Treatment for lymphoblastic lymphomas may result in high morbidity and poor prognosis, highlighting the need for novel targeted therapeutic approaches.
Patients with higher International Prognostic Index scores or advanced-stage disease experienced improved survival when treated with ASCT.
Patients with follicular or marginal zone lymphoma who received lenalidomide with rituximab experienced a median progression-free survival of 39.4 months.
The presence of rheumatologic conditions was also associated with variations in cancer site for both diffuse large B-cell lymphoma and marginal zone lymphoma.
An expert panel reviewed current literature surrounding lymphoma treatment to identify and address any gaps in knowledge.
Presence of multiple mucosal sites at presentation in extranodal marginal zone lymphomas may predict poor survival outcomes.
The combination of pentostatin, cyclophosphamide, and rituximab yielded comparable rates of survival and adverse events to other combination regimens.
Ofatumumab was well tolerated by patients with advanced-stage follicular lymphoma but did not appear superior to other monotherapy agents for this disease.
Results from a phase 1 trial suggested that patients with previously treated mantle cell lymphoma may respond positively to ibrutinib plus palbociclib.
The US FDA provided updated information to women with breast implants and their health care providers on the risk of developing a specific type of lymphoma.
Researchers combined the International Prognostic Index with cell-of-origin subtype to identify patients at high risk for central nervous system relapse.
Changes to the WHO-EORTC classification for primary cutaneous lymphomas were highlighted in a recent review article.
Patients with MYC-rearranged aggressive diffuse large B-cell lymphoma appeared to achieve durable remission with EPOCH-R.
A doublet immunotherapy regimen incorporating the investigational mAb Hu5F9-G4 shows clinical activity in patients with relapsed/refractory non-Hodgkin lymphoma.
“CD19 CAR therapy has paved the way for a new field of medicine based on the genetic instruction of T-cell responses,” according to Dr Michel Sadelin.
Patients who received combined systemic and intraocular treatment had longer failure-free and relapse-free survival.
Over half of evaluable patients who received an infusion of tisagenlecleucel achieved partial or complete response.
A lack of research focusing primarily on older patients with Hodgkin lymphoma has led to an unmet need for effective, less toxic treatment in this population.
The FDA approval was supported by clinical data describing structural and functional characterization, preclinical data, human pharmacokinetic data, clinical immunogenicity data, and other data which showed no clinically meaningful differences between Truxima and Rituxan.
The approval was based on data from a randomized, double-blind, double-dummy, actively controlled trial (ECHELON-2) involving 452 patients with certain PTCLs.
Though the majority of patients with cutaneous T cell lymphomas experience pruritus, the pathophysiology of the symptom is relatively unclear.
Novel molecular technologies for detecting minimal residual disease may offer prognostic value for patients with indolent lymphomas.
Preemptive nucleos(t)ide analog treatment (NAT) was associated with decreased risk of HBV reactivation in patients receiving immunochemotherapy.
Researchers analyzed long-term follow-up data from 2 clinical trials conducted by the German Hodgkin Study Group.
Patients with peripheral T-cell lymphomas have a median overall survival of approximately 6 months.
Conflicting findings regarding the association between plasma Epstein-Barr virus load in PLWHIV and HIV-related lymphomas shows a need for assessment of who benefits from an optimal management of HIV infection and comorbidities.
The current approach to PMBCL diagnosis is not optimal due to the possibility of diagnostic inaccuracy.
Though osteonecrosis has been previously studied in childhood ALL, it has not been evaluated as a side effect of treatment for Hodgkin lymphoma.
Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.
The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.
Baseline ctDNA levels and, separately, measures of molecular response, were prognostic for outcome in patients with diffuse large B-cell lymphoma.
A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.
A retrospective analysis of outcomes demonstrated the influence of rituximab maintenance after R-CHOP or R-CVP for follicular lymphoma in elderly patients.
Outcomes data demonstrated the impact of socioeconomic status and insurance coverage on outcomes for patients with follicular lymphoma by age (younger than 65 and 65 and older).
Signal strength of the receptors used to create CAR-T therapies in lymphoma varied depending on the signaling domain chosen for each investigational construct.
Rituximab plus lenalidomide immunotherapy may be an effective alternative to chemotherapy for patients with follicular lymphoma.
Researchers sought to determine if the newly formed regimen RiBVD was effective and tolerable in patients older than 65 with mantle cell lymphoma.
A phase 2 study was conducted to determine the effectiveness of adding lenalidomide to R-CHOP as a first-line treatment for high-burden follicular lymphoma.
Rituximab plus ibrutinib is the first nonchemotherapy combination regimen approved in Waldenström macroglobulinemia.
This expanded approval was based on results from the iNNOVATE study, a double-blind, placebo-controlled trial evaluating Imbruvica in combination with rituximab vs placebo + rituximab in 150 patients with either relapsed/refractory disease or previously untreated Waldenström’s macroglobulinemia.
New evidence appears to support the potential utility of checkpoint inhibitors in Waldenström macroglobulinemia.
Due to its rarity, there is neither robust evidence nor many completed studies supporting specific treatment regimens in Waldenström macroglobulinemia.
Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.
The effect of MYD88 and CXCR4 mutations on therapy response among patients with treatment-naïve Waldenström macroglobulinemia requires further investigation.
A better understanding of current practices may lead to improved, standardized care, as well as better use of health care resources in Waldenström macroglobulinemia.
A pivotal phase 2 trial indicates promise for another checkpoint drug, this time for patients with classical Hodgkin lymphoma.
[Cancer Management and Research] A review of fertility complications induced by chemotherapy and radiotherapy, as well as possible treatment options for HL patients with fertility problems.
Evidence from previous studies have demonstrated that combined modality therapy with chemotherapy and radiotherapy may improve long-term outcomes in this patient population.
A new analysis of FAB/LMB 96 looked into factors associated with shortened OS among children and adolescents with B-NHL.
Although involved-field radiotherapy (IFRT) has a high level of disease control in patients with follicular lymphoma, relapse frequently occurs; therefore, researchers sought to determine if adding chemotherapy would improve progression-free survival.
Researchers randomly assigned 1030 patients with grade 1 to 3a follicular lymphoma to receive lenalidomide plus rituximab or rituximab plus investigator’s choice chemotherapy of CHOP, CVP, or bendamustine.